Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Adverse Event
17%
Arm
22%
Biopsy Technique
16%
Breast Cancer
59%
Carboplatin
14%
Chemoradiotherapy
17%
Chemotherapy
83%
Childhood Cancer
49%
Cisplatin
20%
Cohort Analysis
14%
Colorectal Carcinoma
18%
Cystectomy
14%
Diseases
38%
Drug Megadose
15%
Event Free Survival
25%
Fluorodeoxyglucose F 18
30%
Hazard Ratio
19%
High Dose Chemotherapy
14%
Hyperthermic Intraperitoneal Chemotherapy
18%
Kidney Tumour
64%
Lymph Node
22%
Malignant Neoplasm
34%
Median Follow Up
18%
Melanoma
18%
Metastatic Carcinoma
16%
Neoplasm
60%
Non Small Cell Lung Cancer
58%
Obstructive Sleep Apnea
18%
Overall Survival
62%
Pediatrics
39%
Pediatrics Patient
16%
Penis Carcinoma
16%
Phallus
14%
Polyethylene Terephthalate
24%
Positron Emission Tomography
33%
Preoperative Chemotherapy
21%
Primary Tumor
16%
Prognostic Factor
17%
Progression Free Survival
16%
Prophylactic Cranial Irradiation
15%
Quality of Life
15%
Radiation Therapy
54%
Randomized Controlled Trial
14%
Recurrent Disease
41%
Scintigraphy
14%
Squamous Cell Carcinoma
18%
Systemic Therapy
19%
Technetium-99
14%
Tumor
56%
Wilms' Tumor
100%
Keyphrases
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
9%
5-year Survival
10%
95% Confidence Interval
24%
Bevacizumab
17%
Breast Cancer
11%
Breast Cancer Patients
10%
Breast Cancer Risk
11%
Capecitabine
11%
Carboplatin
14%
Chemoradiotherapy
9%
Chemotherapy
26%
Cisplatin
9%
Cyclophosphamide
10%
Dutch
18%
Event-free Survival
21%
Hazard Ratio
14%
High Dose
11%
High Risk
12%
High-dose Chemotherapy
10%
Histology
8%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
11%
Intermediate Risk
11%
International Society
16%
Netherlands
13%
Non-small Cell Lung Cancer (NSCLC)
20%
Obstructive Sleep Apnea-hypopnea Syndrome (OSAHS)
13%
Overall Survival
32%
Paclitaxel
9%
Patient Characteristics
8%
Patient Outcomes
15%
Pediatric Oncology
27%
Pediatric Patients
15%
Pediatric Renal Tumors
8%
Penile Carcinoma
11%
Phase I Study
19%
Positron Emission Tomography/computed Tomography (PET/CT)
12%
Preoperative Chemotherapy
15%
Primary Tumor
9%
Prognostic Factors
9%
Progression-free Survival
11%
Prophylactic Cranial Irradiation
10%
Radiotherapy
26%
Randomized Phase III Trial
12%
Randomized Trial
14%
Renal Tumor
32%
Survivors
8%
Treatment Lines
9%
Tumor
28%
Tumor Studies
32%
Wilms Tumor
58%